CRL - Charles River Laboratories International, Inc.
| Previous Close | 119.21 |
| Open | 118.34 |
| Bid | 110.00 x 1100 |
| Ask | 199,999.98 x 800 |
| Day's Range | 116.29 - 119.33 |
| 52 Week Range | 96.70 - 139.72 |
| Volume | 292,416 |
| Avg. Volume | 419,124 |
| Market Cap | 5.656B |
| Beta (3Y Monthly) | 1.07 |
| PE Ratio (TTM) | 42.33 |
| EPS (TTM) | 2.78 |
| Earnings Date | Feb 13, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 136.53 |
- Markit•yesterday
See what the IHS Markit Score report has to say about Charles River Laboratories International Inc.
# Charles River Laboratories International Inc ### NYSE:CRL View full report here! ## Summary * Bearish sentiment is low ## Bearish sentiment Short interest | Positive Short interest is extremely low for CRL with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting CRL. ## Money flow ETF/Index ownership | Neutral ETF activity is neutral. The net inflows of $4.12 billion over the last one-month into ETFs that hold CRL are not among the highest of the last year and have been slowing. ## Economic sentiment PMI by IHS Markit | Neutral According to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year, but is easing. ## Credit worthiness Credit default swap CDS data is not available for this security. Please send all inquiries related to the report to score@ihsmarkit.com. Charts and report PDFs will only be available for 30 days after publishing. This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
- GlobeNewswire•5 days ago
Consolidated Research: 2019 Summary Expectations for Electronic Arts, Charles River Laboratories International, Cooper-Standard, Five Below, Emerge Energy Services LP, and Hornbeck Offshore Services — Fundamental Analysis, Key Performance Indications
NEW YORK, Jan. 18, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
- Business Wire•6 days ago
Charles River Laboratories Schedules Fourth-Quarter 2018 Earnings and 2019 Guidance Release and Conference Call
Charles River Laboratories International, Inc. will release fourth-quarter and full-year 2018 financial results and provide 2019 guidance on Wednesday, February 13th, before the market opens.
- Business Wire•7 days ago
Charles River Laboratories Selected for 2019 Bloomberg Gender-Equality Index
Charles River Laboratories International, Inc. (CRL) today announced that it is pleased to have been selected as one of 230 companies for the 2019 Bloomberg Gender-Equality Index (GEI), which distinguishes companies committed to transparency in gender reporting and advancing gender diversity. For Charles River, the GEI inclusion affirms the Company’s commitment to maintaining a positive and fulfilling work environment for all employees.
- Business Wire•12 days ago
Charles River Laboratories and Atomwise Form a Strategic Alliance to Provide Integrated, Artificial Intelligence-Driven Drug Discovery
Charles River Laboratories International, Inc. (CRL) and Atomwise, Inc. today announced the formation of a strategic alliance that offers clients access to Atomwise’s artificial intelligence (AI)-powered, structure-based, drug design technology, which allows scientists to predict how well a small molecule will bind to a target protein of interest. Leveraging Atomwise’s AI technology and Charles River’s integrated drug discovery platform has the potential to significantly streamline the hit discovery, hit-to-lead, and lead optimization process for clients’ research efforts.
- ACCESSWIRE•14 days ago
Today's Research Reports on Trending Tickers: Syneos Health and Charles River Laboratories International
NEW YORK, NY / ACCESSWIRE / January 9, 2019 / U.S. equities closed up on Tuesday as market participants await details from the recent negotiations in Washington between U.S. and senior Chinese officials. ...
- Simply Wall St.•15 days ago
What Did Charles River Laboratories International, Inc.’s (NYSE:CRL) CEO Take Home Last Year?
James Foster became the CEO of Charles River Laboratories International, Inc. (NYSE:CRL) in 1992. This report will, first, examine the CEO compensation levels in comparison to CEO compensation at companies Read More...
- Business Wire•16 days ago
Charles River Laboratories to Present at J.P. Morgan Healthcare Conference
Charles River Laboratories International, Inc. (CRL) announced today that it will present at the 37th Annual J.P. Morgan Healthcare Conference in San Francisco, California, on Tuesday, January 8th, at 10:00 a.m. PST (1:00 p.m. EST), followed by a question and answer session at 10:30 a.m. PST (1:30 p.m. EST). Management will present an overview of Charles River’s strategic focus, business developments, and recent trends. A live webcast of the presentation and the subsequent question and answer session will be available through a link that will be posted on the Investor Relations section of the Charles River website at ir.criver.com.
- Investor's Business Daily•27 days ago
Why This IBD Stock Of The Day 'Continues To Push For New Highs'
Medpace Holdings is the IBD Stock Of The Day as shares consolidate and its relative strength line approaches recent highs. Medpace Holdings stock is expected to break out at 65.19.
- GuruFocus.com•last month
5 Health Care Stocks in Gurus' Portfolios
According to the GuruFocus All-In-One Screener, the following health care stocks are popular among guru investors. Warning! GuruFocus has detected 2 Warning Sign with CAH. The company, which provides services and products for hospital systems and physicians' offices, has a market cap of $13.5 billion.
- Thomson Reuters StreetEvents•last month
Edited Transcript of CRL earnings conference call or presentation 7-Nov-18 1:30pm GMT
Q3 2018 Charles River Laboratories International Inc Earnings Call
- Insider Monkey•last month
Charles River Laboratories International Inc. (CRL): Are Hedge Funds Right About This Stock?
The fourth quarter was a rough one for most investors, as fears of a rising interest rate environment in the U.S, a trade war with China, and a more or less stagnant Europe, weighed heavily on the minds of investors. Both the S&P 500 and Russell 2000 sank as a result, with the Russell 2000, […]
- Simply Wall St.•2 months ago
Calculating The Intrinsic Value Of Charles River Laboratories International Inc (NYSE:CRL)
How far off is Charles River Laboratories International Inc (NYSE:CRL) from its intrinsic value? Using the most recent financial data, I am going to take a look at whether the Read More...
- GlobeNewswire•2 months ago
Investor Expectations to Drive Momentum within Raytheon, S&P Global, Teledyne Technologies, Nordstrom, Charles River Laboratories International, and U.S. Silica — Discovering Underlying Factors of Influence
NEW YORK, Dec. 07, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
- CNBC•2 months ago
Cramer's lightning round: Take a long-term view on JP Morgan's stock
Jim Cramer rips through his responses to callers' stock questions, including one on a high-profile bank name that had a volatile day.
- Zacks•2 months ago
SYNH vs. CRL: Which Stock Is the Better Value Option?
SYNH vs. CRL: Which Stock Is the Better Value Option?
- Investor's Business Daily•2 months ago
IBD 50 Stock Breaks Out Amid Boost For Medical Research Stocks
PRA Health stock broke out Thursday amid a broad boost for medical research stocks. Medical research stocks are benefiting from inflows into biotechs.
- Business Wire•2 months ago
Charles River Laboratories to Present at Evercore ISI Investor Conference
Charles River Laboratories International, Inc. (CRL) announced today that it will present at the Evercore ISI HealthConX Conference in Boston on Thursday, November 29th, at 11:00 a.m. ET. Management will present an overview of Charles River’s strategic focus and business developments. A live webcast of the presentation will be available through a link that will be posted on the Investor Relations section of the Charles River website at ir.criver.com.
- American City Business Journals•2 months ago
Employees allege racial discrimination at Charles River Laboratories facility
A group of current and former Charles River Laboratories employees is suing the company, alleging that the lab services company has ignored their unequal pay and racial discrimination complaints.
- Business Wire•2 months ago
Charles River Laboratories Continues Commitment to Oncology Drug Discovery
Charles River Laboratories International, Inc. (CRL) today announced new additions to the Tumor Model Compendium. Charles River’s Compendium provides access to a comprehensive collection of well-established tumor models for early-stage oncology research. The most recent Compendium update adds gastric and liver models, as well as new molecular data for leukemia, liver cancer, lymphoma, breast cancer and ovarian cancer.
Markit•2 months agoSee what the IHS Markit Score report has to say about Charles River Laboratories International Inc.
Charles River Laboratories International Inc NYSE:CRL
Motley Fool•3 months agoCharles River Laboratories International Inc (CRL) Q3 2018 Earnings Conference Call Transcript
CRL earnings call for the period ending September 29, 2018.
- Simply Wall St.•3 months ago
Charles River Laboratories International Inc (NYSE:CRL): Will The Growth Last?
Looking at Charles River Laboratories International Inc’s (NYSE:CRL) earnings update in June 2018, it seems that analyst forecasts are substantially optimistic, with profits predicted to ramp up by an impressive Read More...
- Zacks•3 months ago
Charles River Laboratories (CRL) Q3 Earnings and Revenues Top Estimates
Charles River (CRL) delivered earnings and revenue surprises of 10.87% and 3.12%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
- Associated Press•3 months ago
Charles River: 3Q Earnings Snapshot
The Wilmington, Massachusetts-based company said it had net income of $1.22 per share. Earnings, adjusted for one-time gains and costs, were $1.53 per share. The results surpassed Wall Street expectations. ...
